A form of necrotizing non-granulomatous inflammation occurring primarily in medium-sized ARTERIES, often with microaneurysms. It is characterized by muscle, joint, and abdominal pain resulting from arterial infarction and scarring in affected organs. Polyarteritis nodosa with lung involvement is called CHURG-STRAUSS SYNDROME.
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
INFLAMMATION of any ARTERIES.
Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.
A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and kidneys. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against neutrophil proteinase-3 (WEGENER AUTOANTIGEN).
Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area.
A primary systemic vasculitis of small- and some medium-sized vessels. It is characterized by a tropism for kidneys and lungs, positive association with anti-neutrophil cytoplasmic antibodies (ANCA), and a paucity of immunoglobulin deposits in vessel walls.
A heterogeneous group of diseases characterized by inflammation and necrosis of the blood vessel walls.
Inflammation of the connective and adipose tissues surrounding the KIDNEY.
Administration of high doses of pharmaceuticals over short periods of time.
Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.
Death and putrefaction of tissue usually due to a loss of blood supply.
Disorder characterized by a vasculitic syndrome associated with exposure to an antigen such as a drug, infectious agent, or other foreign or endogenous substance. Its pathophysiology includes immune complex deposition and a wide range of skin lesions. Hypersensitivity or allergy is present in some but not all cases.
Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.
Formation of an infarct, which is NECROSIS in tissue due to local ISCHEMIA resulting from obstruction of BLOOD CIRCULATION, most commonly by a THROMBUS or EMBOLUS.
Pathological processes of the TESTIS.
Pathological outpouching or sac-like dilatation in the wall of any blood vessel (ARTERIES or VEINS) or the heart (HEART ANEURYSM). It indicates a thin and weakened area in the wall which may later rupture. Aneurysms are classified by location, etiology, or other characteristics.
A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum.
A condition characterized by the presence of abnormal quantities of CRYOGLOBULINS in the blood. Upon cold exposure, these abnormal proteins precipitate into the microvasculature leading to restricted blood flow in the exposed areas.

Familial Mediterranean fever--renal involvement by diseases other than amyloid. (1/205)

BACKGROUND: In patients with familial Mediterranean fever (FMF) renal involvement is usually in the form of AA amyloidosis. There is increasing evidence that renal involvement may be due to diseases other than amyloid as well. METHODS: Amongst 302 children with FMF we observed and followed 28 with typical clinical and laboratory features of vasculitis. The diagnosis of FMF was established according to the Tel Hashomer criteria. RESULTS: Polyarteritis nodosa, protracted febrile attacks and Henoch-Schonlein purpura were diagnosed in 4, 13, and 11 patients, respectively. The presentation was often difficult to distinguish from FMF attacks, but protracted febrile attacks lasting several weeks, hypertension, thrombocytosis, and dramatic responses to corticosteroid therapy that were observed in many cases were different from what is observed in classical FMF. CONCLUSIONS: We suggest that FMF, perhaps as a consequence of impaired control of inflammatory responses, predisposes to vasculitis with renal involvement.  (+info)

Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. (2/205)

OBJECTIVE: Pneumonia due to Pneumocystis carinii has been increasingly reported in patients with connective tissue diseases, but the frequency of this complication is not known. We sought to determine the frequency of P carinii pneumonia (PCP) in patients with connective tissue diseases, and to determine the role that a hospital's acquired immunodeficiency syndrome (AIDS)-related experience may have in the diagnosis of PCP in these patients. METHODS: We used a state hospitalization registry to identify all patients with PCP and either rheumatoid arthritis, systemic lupus erythematosus, Wegener's granulomatosis, polymyositis, dermatomyositis, polyarteritis nodosa, or scleroderma who had an emergent or urgent hospitalization in California from 1983 to 1994. We compared patient and hospital characteristics between these patients and patients with connective tissue diseases hospitalized with other types of pneumonia. RESULTS: Two hundred twenty-three patients with connective tissue diseases were diagnosed with PCP in the 12-year study period. The frequency of PCP ranged from 89 cases/10,000 hospitalizations/year in patients with Wegener's granulomatosis to 2 cases/10,000 hospitalizations/year in patients with rheumatoid arthritis. Compared with 5,457 patients with connective tissue diseases and pneumonia due to other organisms, patients with PCP were more likely to be younger, to be male, to have private medical insurance, and to have systemic lupus erythematosus, Wegener's granulomatosis, inflammatory myopathy, or polyarteritis nodosa rather than rheumatoid arthritis, and were less likely to be African American. Hospital size, teaching status, urban/rural location, proportion of admissions due to AIDS or PCP, and proportion of patients with pneumonia undergoing bronchoscopy were each associated with the likelihood of diagnosis of PCP in univariate analyses, but only the number of patients with PCP being treated at a hospital (odds ratio [OR] 1.03 for each additional 10 cases/year, 95% confidence interval [95% CI] 1.01-1.05) was associated with the likelihood of diagnosis of PCP in multivariate analyses. Patients were also somewhat more likely to be diagnosed with PCP if there had previously been a case of PCP in a patient with a connective tissue disease at the same hospital (OR 135, 95% CI 0.98-1.85). In-hospital mortality was 45.7%, and was unrelated to hospital characteristics. CONCLUSION: PCP is an uncommon, but often fatal, occurrence in patients with connective tissue disease. A hospital's prior experience with patients with PCP is associated with the likelihood that this condition is diagnosed in patients with connective tissue diseases who present with pneumonia, suggesting that diagnostic suspicion is an important factor in the correct identification of affected patients.  (+info)

Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection. (3/205)

Persistent infections with human parvovirus B19 (B19) associated with debilitating chronic disease have been described, although evidence linking B19 to these more unusual clinical outcomes has been inconclusive. Recent reports have suggested that the development of antibodies to the B19 nonstructural protein (NS1) following B19 infection might be linked to development of severe arthropathy and chronic infection. To confirm these findings, the C-terminal region of the NS1 protein was expressed for use in Western blot assays for detection of anti-NS1 IgG antibodies in human serum. Among 91 persons tested, 0 of 20 not previously infected with B19, 9(36%) of 25 with past B19 infection, and 5 (12.5%) of 40 with recent B19 infection, had detectable anti-NS1 antibodies. Of 6 persons with chronic B19 infection, 2 had detectable antibodies to NS1. The presence of anti-NS1 antibodies did not appear to correlate with unusual clinical outcomes or chronic B19 infection.  (+info)

No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. (4/205)

ANCA, implicated as having a pathogenic role in systemic vasculitis, can activate tumour necrosis factor-alpha (TNF-alpha)-primed neutrophils by cross-linking surface-expressed ANCA antigens with neutrophil FcgammaRIIa receptors to release reactive oxygen species. The FcgammaRIIa receptor exists as polymorphic variants, R131 and H131, which differ in their ability to ligate human IgG2 and IgG3. Neutrophils homozygous for the FcgammaRIIa-H131 allotype bind more efficiently to IgG3 than the FcgammaRIIa-R131 allotype and are the only human FcgammaR which bind IgG2. Our aim was to determine whether the homozygous FcgammaRIIa-H131 individuals are more susceptible to developing ANCA-associated systemic vasculitis and nephritis due to differential IgG binding and activation. FcgammaRIIa allotype was determined by both allele-specific polymerase chain reaction (PCR) and Southern blotting with allele-specific oligonucleotide probes end-labelled with 32P-gammaATP, after PCR amplification of genomic FcgammaRIIa DNA in 107 Caucasian patients with ANCA+ vasculitis (of whom 89 had renal disease) and 100 ethnically matched controls. Phenotyping of neutrophil FcgammaRIIa alleles was confirmed in some patients by quantitative flow cytometry using murine MoAbs 41H16 and IV.3. Of the patients with ANCA+ systemic vasculitis, 75 had ANCA with specificity for proteinase 3 and 32 with specificity for myeloperoxidase. Overall, no skewing in FcgammaRIIa allotypes was seen in patients compared with controls. No significant increase of the FcgammaRIIa-H131 allotype was found amongst patients irrespective of ANCA specificity, and no association between the FcgammaRIIa allotype and nephritis was found. Our data suggest that the FcgammaRIIa receptor allotype is not a major factor predisposing to the development of ANCA+ systemic vasculitis, or to nephritis.  (+info)

Polyangiitis overlap syndrome with eosinophilia associated with an elevated serum level of major basic protein. (5/205)

Polyangiitis overlap syndrome is a new disease entity and the reported cases in the literature are still limited. We describe a female patient presenting with finger ulcers, skin eruptions, pleural effusion, interstitial pneumonia and eosinophilia. Skin biopsy showed systemic small-sized angiitis and thrombosis. She was diagnosed as having polyangiitis overlap syndrome and was successfully then treated with corticosteroid. It is also of interest that the disease activity was correlated with the number of eosinophils in peripheral blood. The measurement of the serum level of major basic protein released from eosinophils functioning as a coagulant indicated the possible association of eosinophilia with thrombosis and polyangiitis.  (+info)

The incidence and development of periarteritis nodosa in testicular arterioles and mesenteric arteries of spontaneously hypertensive rats. (6/205)

We sought to clarify the incidence, vessel-size and age distribution of periarteritis nodosa in rats occurring as a vascular lesion in malignant hypertension. Stroke-prone spontaneously hypertensive and stroke-resistant spontaneously hypertensive rat strains were studied, as well as Wistar-Kyoto control rats. Mesenteric arteries and testicular arteries were examined histologically. Additionally, electron microscopy investigation was carried out on one stroke-prone hypertensive rat and one control. Periarteritis nodosa lesions were present in testicular arterioles in 57.1%, and mesenteric arteries in 28.6%, of stroke-prone hypertensive rats aged 9.5 mo. Lesion incidence at these sites was 100% and 60% respectively in 10 stroke-prone rats aged 15.5 mo, and 42.9% and 28.6% in stroke-resistant hypertensive rats aged 22.5 mo. In contrast, the incidence rate was 0% at both sites in stroke-resistant hypertensive rats aged 8 or 14.5 mo, and in control rats aged 9.5 or 25 mo. In stroke-prone rats, arteritis lesion counts (mean+/-SD) in testicular sections were 11.6+/-17 at age 9.5 mo and 96.3+/-60.9 at age 15.5 mo. In individual lesion scoring, arteritis was more severe in mesenteric arteries than in testicular arterioles. For arteriolar lesion distribution patterns in testicular sections, partial peripheral, partial peripheral plus central, and circumferential patterns were all noted. In conclusion, periarteritis nodosa in hypertensive stroke-prone rats occurs earlier in testicular arterioles, but attains greater severity in the mesenteric artery.  (+info)

Primary renal vasculitis in Norfolk--increasing incidence or increasing recognition? (7/205)

BACKGROUND: The incidence of renal vasculitis has previously been estimated using histological definitions or only a single clinical diagnosis, e.g. Wegener's Granulomatosis (WG). Our hospital is the single referral centre for the former Norwich Health Authority (NHA) which encompasses a stable, homogeneous, well-defined and studied population. We estimated the overall incidence of primary renal vasculitis and the incidence within individual clinical disease classifications. METHODS: All cases of primary renal vasculitis diagnosed within the NHA over 66 months (1992-1997) were identified by review of renal biopsies, the Norfolk Vasculitis Register, hospital discharge summaries and plasmapheresis records. Patients were classified using the 1990 American College of Rheumatology criteria for Polyarteritis Nodosa (PAN), Churg Strauss Syndrome (CSS) and Henoch-Schonlein Purpura; the Chapel Hill Consensus Conference Definitions for Microscopic Polyangiitis (mPA) and the Lanham criteria for CSS. Incidence figures were calculated using the NHA adult population of 413747 (1994). Ninety-five per cent confidence intervals (C.I.) were calculated using the poisson distribution. RESULTS: The overall annual incidence for primary renal vasculitis was 18/million (C.I. 12.9-24.4). The annual incidence of renal involvement of individual diseases was as follows: WG 7.9/million (95% C.I. 4.7-12.5); mPA 7.5/million (95% C. I. 4.4-12.0); PAN 7.0/million (95% C.I. 4.0-11.4); HSP 3.1/million (95% C.I. 1.2-6.3); CSS 1.3/million (95% C.I. 0.3-3.9). CONCLUSIONS: The annual incidence for primary renal vasculitis overall and the individual subtypes in Norfolk is much higher than previous European estimates. This may reflect an increasing incidence in primary renal vasculitis with time or underestimation in previous studies. However the incidence of renal vasculitis in our population is markedly lower than reported in Kuwait. There may therefore be true variation in incidence between populations which could have implications for the aetiology of primary vasculitis.  (+info)

A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. (8/205)

OBJECTIVE: To test the usefulness of the Chapel Hill nomenclature, supplemented with surrogate parameters, as diagnostic criteria for primary vasculitides. METHODS: To prospectively evaluate vasculitis patients according to a standardised clinical and para-clinical programme. In accordance with the Chapel Hill publication surrogate parameters were used: proteinuria, haematuria and red blood cell casts (glomerulonephritis), angiographic or ultrasonic demonstration of aneurysms or stenoses (arteritis), radiological lung infiltrates or cavitations of more than one month's duration (granuloma in the lungs), bloody nasal discharge or crusts, chronic sinusitis, otitis and/or mastoiditis, bone and/or cartilage destruction, and acute hearing loss (granuloma in upper airways). RESULTS: The following entities were diagnosed: giant cell arteritis (n=14), Takayasu arteritis (n=1), polyarteritis nodosa (n=2), Wegener's granulomatosis (n=27), Churg-Strauss syndrome (n=2), microscopic polyangiitis (n=12), Henoch-Schonlein purpura (n=2), cutaneous leucocytoclastic angiitis (n=37), and secondary vasculitis (n=21). Giant cell arteritis and cutaneous leucocytoclastic angiitis were in all cases diagnosed by biopsy. Using the Chapel Hill nomenclature supplemented with surrogate parameters, only 8 of 27 patients were diagnosed with Wegener's granulomatosis, and 3 of 12 cases with microscopic polyangiitis. The number of patients in the remaining diagnostic entities were considered to few to evaluate. CONCLUSIONS: The Chapel Hill nomenclature, supplemented with surrogate parameters, failed to act as diagnostic criteria in Wegener's granulomatosis and microscopic polyangiitis. The following diagnostic criteria are proposed for Wegener's granulomatosis: (1) Biopsy or surrogate parameter for granulomatous inflammation in the respiratory system and (2) Biopsy verified necrotising vasculitis in small to medium sized vessels or biopsy/surrogate parameter for glomerulonephritis or positive PR3-ANCA test and (3) Lack of eosinophilia in blood and biopsy samples. The following diagnostic criteria are proposed for microscopic polyangiitis: (1) Biopsy verified necrotising vasculitis in small vessels and/or glomerulonephritis with few or no immune deposits and (2) Involvement of more than one organ system as indicated by biopsy verified vasculitis in small to medium sized vessels or surrogate parameter for glomerulonephritis and (3) Lack of biopsy and surrogate parameter for granulomatous inflammation in the respiratory system. Using these criteria all Wegener's patients and 9 of 12 patients with microscopic polyangiitis could be diagnosed.  (+info)

Polyarteritis nodosa (PAN) is a rare, systemic necrotizing vasculitis that affects medium-sized and small muscular arteries. It is characterized by inflammation and damage to the walls of the arteries, leading to the formation of microaneurysms (small bulges in the artery wall) and subsequent narrowing or complete occlusion of the affected vessels. This can result in tissue ischemia (reduced blood flow) and infarction (tissue death), causing a wide range of clinical manifestations that vary depending on the organs involved.

The exact cause of PAN remains unclear, but it is believed to involve an autoimmune response triggered by various factors such as infections or exposure to certain drugs. The diagnosis of PAN typically requires a combination of clinical findings, laboratory tests, and imaging studies, often supported by histopathological examination of affected tissues. Treatment usually involves the use of immunosuppressive medications to control inflammation and prevent further damage to the arteries and organs.

Vasculitis is a group of disorders characterized by inflammation of the blood vessels, which can cause changes in the vessel walls including thickening, narrowing, or weakening. These changes can restrict blood flow, leading to organ and tissue damage. The specific symptoms and severity of vasculitis depend on the size and location of the affected blood vessels and the extent of inflammation. Vasculitis can affect any organ system in the body, and its causes can vary, including infections, autoimmune disorders, or exposure to certain medications or chemicals.

Arteritis is a medical condition characterized by inflammation of the arteries. It is also known as vasculitis of the arteries. The inflammation can cause the walls of the arteries to thicken and narrow, reducing blood flow to affected organs or tissues. There are several types of arteritis, including:

1. Giant cell arteritis (GCA): Also known as temporal arteritis, it is a condition that mainly affects the large and medium-sized arteries in the head and neck. The inflammation can cause headaches, jaw pain, scalp tenderness, and vision problems.
2. Takayasu's arteritis: This type of arteritis affects the aorta and its major branches, mainly affecting young women. Symptoms include fever, weight loss, fatigue, and decreased pulse in the arms or legs.
3. Polyarteritis nodosa (PAN): PAN is a rare systemic vasculitis that can affect medium-sized arteries throughout the body. It can cause a wide range of symptoms, including fever, rash, abdominal pain, and muscle weakness.
4. Kawasaki disease: This is a type of arteritis that mainly affects children under the age of 5. It causes inflammation in the blood vessels throughout the body, leading to fever, rash, swollen lymph nodes, and red eyes.

The exact cause of arteritis is not fully understood, but it is believed to be an autoimmune disorder, where the body's immune system mistakenly attacks its own tissues. Treatment for arteritis typically involves medications to reduce inflammation and suppress the immune system.

Churg-Strauss syndrome (CSS), also known as eosinophilic granulomatosis with polyangiitis (EGPA), is a rare autoimmune disorder characterized by inflammation of small- to medium-sized blood vessels (vasculitis) and the presence of eosinophils, a type of white blood cell. The syndrome typically affects multiple organ systems, including the respiratory tract, peripheral nerves, skin, heart, and kidneys.

The classic triad of symptoms includes asthma, allergies, and peripheral blood eosinophilia (high levels of eosinophils in the blood). Other common features include sinusitis, rhinitis, cough, shortness of breath, skin rashes, neuropathy (nerve damage), and cardiac involvement.

The exact cause of Churg-Strauss syndrome is not well understood, but it is believed to involve an abnormal immune response in genetically susceptible individuals. Treatment typically involves the use of immunosuppressive medications to control inflammation and prevent organ damage. Corticosteroids are often used as a first-line therapy, while other agents such as cyclophosphamide or rituximab may be added for more severe cases.

Wegener Granulomatosis is a rare, chronic granulomatous vasculitis that affects small and medium-sized blood vessels. It is also known as granulomatosis with polyangiitis (GPA). The disease primarily involves the respiratory tract (nose, sinuses, trachea, and lungs) and kidneys but can affect other organs as well.

The characteristic features of Wegener Granulomatosis include necrotizing granulomas, vasculitis, and inflammation of the blood vessel walls. These abnormalities can lead to various symptoms such as cough, shortness of breath, nosebleeds, sinus congestion, skin lesions, joint pain, and kidney problems.

The exact cause of Wegener Granulomatosis is unknown, but it is believed to be an autoimmune disorder where the body's immune system mistakenly attacks its own tissues and organs. The diagnosis of Wegener Granulomatosis typically involves a combination of clinical symptoms, laboratory tests, imaging studies, and biopsy findings. Treatment usually includes immunosuppressive therapy to control the inflammation and prevent further damage to the affected organs.

Vascular skin diseases are a group of medical conditions that affect the blood vessels in the skin. These disorders can be caused by problems with the structure or function of the blood vessels, which can lead to various symptoms such as redness, discoloration, pain, itching, and ulcerations. Some examples of vascular skin diseases include:

1. Rosacea: a chronic skin condition that causes redness, flushing, and visible blood vessels in the face.
2. Eczema: a group of inflammatory skin conditions that can cause redness, itching, and dryness. Some types of eczema, such as varicose eczema, are associated with problems with the veins.
3. Psoriasis: an autoimmune condition that causes red, scaly patches on the skin. Some people with psoriasis may also develop psoriatic arthritis, which can affect the blood vessels in the skin and joints.
4. Vasculitis: a group of conditions that cause inflammation of the blood vessels. This can lead to symptoms such as redness, pain, and ulcerations.
5. Livedo reticularis: a condition that causes a net-like pattern of discoloration on the skin, usually on the legs. It is caused by abnormalities in the small blood vessels.
6. Henoch-Schönlein purpura: a rare condition that causes inflammation of the small blood vessels, leading to purple spots on the skin and joint pain.
7. Raynaud's phenomenon: a condition that affects the blood vessels in the fingers and toes, causing them to become narrow and restrict blood flow in response to cold temperatures or stress.

Treatment for vascular skin diseases depends on the specific condition and its severity. It may include medications, lifestyle changes, and in some cases, surgery.

Microscopic Polyangiitis (MPA) is a rare type of vasculitis, which is a group of disorders that cause inflammation in the blood vessels. In MPA, the small blood vessels in various organs become inflamed and damaged, leading to symptoms that can affect multiple organ systems.

The term "microscopic" refers to the fact that the diagnosis of this condition typically requires examination of tissue samples under a microscope to see the characteristic patterns of inflammation and damage in the small blood vessels.

MPA is an autoimmune disorder, which means that the body's immune system mistakenly attacks its own tissues and organs. In MPA, the immune system produces abnormal antibodies called ANCA (antineutrophil cytoplasmic antibodies) that target certain proteins in the white blood cells, leading to their activation and subsequent damage to the blood vessels.

The symptoms of MPA can vary widely depending on which organs are affected, but they may include fever, fatigue, weight loss, joint pain, skin rashes, cough, shortness of breath, and kidney problems such as proteinuria and hematuria. Treatment typically involves the use of immunosuppressive medications to suppress the overactive immune system and reduce inflammation in the blood vessels.

Systemic vasculitis is a group of disorders characterized by inflammation of the blood vessels (vasculitis) that can affect various organs and systems throughout the body. This condition can cause damage to the walls of the blood vessels, leading to narrowing, blockage, or weakening of the vessel walls, which can further result in reduced blood flow, tissue damage, and organ dysfunction.

The symptoms of systemic vasculitis depend on the severity and location of the affected blood vessels. They may include fever, fatigue, weight loss, joint pain, skin rashes or lesions, muscle weakness, nerve damage, and organ dysfunction such as kidney failure, lung disease, or gastrointestinal bleeding.

Systemic vasculitis can be caused by various factors, including infections, autoimmune diseases, medications, and underlying medical conditions. The diagnosis of systemic vasculitis typically involves a combination of physical examination, laboratory tests, imaging studies, and sometimes biopsy of the affected tissue. Treatment may include corticosteroids, immunosuppressive drugs, and other medications to control inflammation and prevent organ damage.

Perinephritis is a medical term that refers to the inflammation of the tissues surrounding the kidney. It is a relatively rare condition that can result from various causes, including bacterial infections, fungal infections, or chemical irritants. In some cases, perinephritis may also occur as a complication of kidney surgery or trauma to the kidney.

The symptoms of perinephritis can vary depending on the severity and cause of the inflammation. They may include fever, abdominal or back pain, nausea, vomiting, and difficulty urinating. In severe cases, perinephritis can lead to serious complications such as sepsis, kidney failure, or even death if left untreated.

Diagnosis of perinephritis typically involves a combination of physical examination, medical history, laboratory tests, and imaging studies such as ultrasound, CT scan, or MRI. Treatment usually involves antibiotics to treat any underlying infection, as well as supportive care to manage symptoms and prevent complications. In some cases, surgery may be necessary to drain any accumulated pus or fluid in the perinephric area.

Pulse therapy, in the context of drug treatment, refers to a therapeutic regimen where a medication is administered in large doses for a short period of time, followed by a break or "drug-free" interval before the next dose. This cycle is then repeated at regular intervals. The goal of pulse therapy is to achieve high concentrations of the drug in the body to maximize its therapeutic effect while minimizing overall exposure and potential side effects.

This approach is often used for drugs that have a long half-life or slow clearance, as it allows for periodic "washing out" of the drug from the body. Pulse therapy can also help reduce the risk of developing drug resistance in certain conditions like rheumatoid arthritis and tuberculosis. Common examples include pulse methotrexate for rheumatoid arthritis and intermittent preventive treatment with anti-malarial drugs.

It is important to note that the use of pulse therapy should be based on a thorough understanding of the drug's pharmacokinetics, therapeutic index, and potential adverse effects. Close monitoring of patients undergoing pulse therapy is essential to ensure safety and efficacy.

Antineutrophil cytoplasmic antibodies (ANCAs) are a type of autoantibody that specifically target certain proteins in the cytoplasm of neutrophils, which are a type of white blood cell. These antibodies are associated with several types of vasculitis, which is inflammation of the blood vessels.

There are two main types of ANCAs: perinuclear ANCAs (p-ANCAs) and cytoplasmic ANCAs (c-ANCAs). p-ANCAs are directed against myeloperoxidase, a protein found in neutrophil granules, while c-ANCAs target proteinase 3, another protein found in neutrophil granules.

The presence of ANCAs in the blood can indicate an increased risk for developing certain types of vasculitis, such as granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA). ANCA testing is often used in conjunction with other clinical findings to help diagnose and manage these conditions.

It's important to note that while the presence of ANCAs can indicate an increased risk for vasculitis, not everyone with ANCAs will develop the condition. Additionally, ANCAs can also be found in some individuals without any associated disease, so their presence should be interpreted in the context of other clinical findings.

Gangrene is a serious and potentially life-threatening condition that occurs when there is a loss of blood flow to a specific area of the body, resulting in tissue death. It can be caused by various factors such as bacterial infections, trauma, diabetes, vascular diseases, and smoking. The affected tissues may become discolored, swollen, and emit a foul odor due to the accumulation of bacteria and toxins.

Gangrene can be classified into two main types: dry gangrene and wet (or moist) gangrene. Dry gangrene develops slowly and is often associated with peripheral arterial disease, which reduces blood flow to the extremities. The affected area turns black and shriveled as it dries out. Wet gangrene, on the other hand, progresses rapidly due to bacterial infections that cause tissue breakdown and pus formation. This type of gangrene can spread quickly throughout the body, leading to severe complications such as sepsis and organ failure if left untreated.

Treatment for gangrene typically involves surgical removal of the dead tissue (debridement), antibiotics to control infections, and sometimes revascularization procedures to restore blood flow to the affected area. In severe cases where the infection has spread or the damage is irreversible, amputation of the affected limb may be necessary to prevent further complications and save the patient's life.

Leukocytoclastic vasculitis, cutaneous is a type of vasculitis that is limited to the skin. Vasculitis refers to inflammation of the blood vessels, which can cause damage to the vessel walls and impair blood flow to various tissues in the body. In leukocytoclastic vasculitis, the small blood vessels (capillaries and venules) in the skin become inflamed, leading to damage and destruction of the vessel walls.

The term "leukocytoclastic" refers to the presence of nuclear debris from white blood cells (leukocytes) that have been destroyed within the affected blood vessels. This type of vasculitis is often associated with the deposition of immune complexes (formed by the interaction between antibodies and antigens) in the walls of the blood vessels, which triggers an inflammatory response.

Cutaneous leukocytoclastic vasculitis typically presents as palpable purpura (small to large, raised, purple or red spots on the skin), usually located on the lower extremities, but can also affect other areas of the body. Other symptoms may include burning or itching sensations in the affected area, and in some cases, ulcers or necrosis (tissue death) may occur.

The diagnosis of cutaneous leukocytoclastic vasculitis is typically made based on clinical presentation, laboratory tests, and histopathological examination of a skin biopsy specimen. Treatment usually involves addressing any underlying causes or triggers, as well as managing symptoms with medications such as corticosteroids or immunosuppressive agents.

Plasma exchange, also known as plasmapheresis, is a medical procedure where the liquid portion of the blood (plasma) is separated from the blood cells. The plasma, which may contain harmful substances such as antibodies, clotting factors, or toxins, is then removed and replaced with fresh plasma or a plasma substitute. This process helps to remove the harmful substances from the blood and allows the body to replenish its own plasma with normal components. Plasma exchange is used in the treatment of various medical conditions including autoimmune diseases, poisonings, and certain types of kidney diseases.

Infarction is the term used in medicine to describe the death of tissue (also known as an "area of necrosis") due to the lack of blood supply. This can occur when a blood vessel that supplies oxygen and nutrients to a particular area of the body becomes blocked or obstructed, leading to the deprivation of oxygen and nutrients necessary for the survival of cells in that region.

The blockage in the blood vessel is usually caused by a clot (thrombus) or an embolus, which is a small particle that travels through the bloodstream and lodges in a smaller vessel. The severity and extent of infarction depend on several factors, including the size and location of the affected blood vessel, the duration of the obstruction, and the presence of collateral circulation (alternative blood vessels that can compensate for the blocked one).

Common examples of infarctions include myocardial infarction (heart attack), cerebral infarction (stroke), and pulmonary infarction (lung tissue death due to obstruction in the lung's blood vessels). Infarctions can lead to various symptoms, depending on the affected organ or tissue, and may require medical intervention to manage complications and prevent further damage.

Testicular diseases refer to a range of conditions that affect the testicles, the male reproductive organs located in the scrotum. These diseases can affect either one or both testicles and may cause pain, swelling, or impact fertility. Here are some examples of testicular diseases:

1. Testicular cancer: A malignant tumor that develops in the testicle. It is a relatively rare cancer but is highly treatable if detected early.
2. Testicular torsion: A surgical emergency that occurs when the spermatic cord, which supplies blood to the testicle, becomes twisted, cutting off the blood flow.
3. Epididymitis: An infection or inflammation of the epididymis, a coiled tube that stores and carries sperm from the testicle.
4. Orchitis: An infection or inflammation of the testicle itself. It can occur on its own or as a complication of mumps.
5. Hydrocele: A fluid-filled sac that forms around the testicle, causing swelling.
6. Varicocele: Enlarged veins in the scrotum that can cause pain and affect fertility.
7. Inguinal hernia: A condition where a portion of the intestine or fat protrudes through a weakened area in the abdominal wall, often appearing as a bulge in the groin or scrotum.
8. Testicular trauma: Injury to the testicle, which can result from accidents, sports injuries, or other causes.
9. Undescended testicles: A condition where one or both testicles fail to descend from the abdomen into the scrotum before birth.

It is essential for men to perform regular self-examinations to check for any unusual lumps, swelling, or pain in the testicles and seek medical attention if they notice any changes.

An aneurysm is a localized, balloon-like bulge in the wall of a blood vessel. It occurs when the pressure inside the vessel causes a weakened area to swell and become enlarged. Aneurysms can develop in any blood vessel, but they are most common in arteries at the base of the brain (cerebral aneurysm) and the main artery carrying blood from the heart to the rest of the body (aortic aneurysm).

Aneurysms can be classified as saccular or fusiform, depending on their shape. A saccular aneurysm is a round or oval bulge that projects from the side of a blood vessel, while a fusiform aneurysm is a dilated segment of a blood vessel that is uniform in width and involves all three layers of the arterial wall.

The size and location of an aneurysm can affect its risk of rupture. Generally, larger aneurysms are more likely to rupture than smaller ones. Aneurysms located in areas with high blood pressure or where the vessel branches are also at higher risk of rupture.

Ruptured aneurysms can cause life-threatening bleeding and require immediate medical attention. Symptoms of a ruptured aneurysm may include sudden severe headache, neck stiffness, nausea, vomiting, blurred vision, or loss of consciousness. Unruptured aneurysms may not cause any symptoms and are often discovered during routine imaging tests for other conditions.

Treatment options for aneurysms depend on their size, location, and risk of rupture. Small, unruptured aneurysms may be monitored with regular imaging tests to check for growth or changes. Larger or symptomatic aneurysms may require surgical intervention, such as clipping or coiling, to prevent rupture and reduce the risk of complications.

The hepatic artery is a branch of the celiac trunk or abdominal aorta that supplies oxygenated blood to the liver. It typically divides into two main branches, the right and left hepatic arteries, which further divide into smaller vessels to supply different regions of the liver. The hepatic artery also gives off branches to supply other organs such as the gallbladder, pancreas, and duodenum.

It's worth noting that there is significant variability in the anatomy of the hepatic artery, with some individuals having additional branches or variations in the origin of the vessel. This variability can have implications for surgical procedures involving the liver and surrounding organs.

Cryoglobulinemia is a medical condition characterized by the presence of abnormal proteins called cryoglobulins in the blood. These proteins become insoluble at lower temperatures and can form immune complexes that can cause inflammation and damage to small blood vessels when they precipitate in cooler parts of the body.

Cryoglobulinemia is often associated with underlying conditions such as autoimmune diseases (such as rheumatoid arthritis or lupus), chronic infections (such as hepatitis C), and certain types of cancer (such as lymphoma). Symptoms can vary widely, but may include purpura (purple spots on the skin), joint pain, peripheral neuropathy (nerve damage causing numbness or weakness), fatigue, and kidney problems.

The diagnosis of cryoglobulinemia is typically made by detecting cryoglobulins in the blood through a special test that requires the blood sample to be kept at cold temperatures. Treatment for cryoglobulinemia depends on the underlying cause, but may include medications such as corticosteroids, immunosuppressants, or chemotherapy drugs.

... rarely affects the blood vessels of the lungs and this feature can help to differentiate it from other ... In polyarteritis nodosa, small aneurysms are strung like the beads of a rosary, therefore making this "rosary sign" an ... Polyarteritis nodosa is more common in people with hepatitis B infection. The medical eponyms Kussmaul disease or Kussmaul- ... 2], Entry in Polyarteritis Nodosa Follow-up article "Bigger Than Life". The Criterion Collection. Retrieved 2021-07-16. ( ...
Polyarteritis nodosa (PAN). Systemic necrotizing vasculitis and aneurysm formation affecting both medium and small arteries. If ... Angiograms of mesenteric or renal arteries in polyarteritis nodosa may show aneurysms, occlusions, and vascular wall ... Methamphetamine and other sympathomimetics can cause a cerebral vasculitis alongside polyarteritis nodosa like systemic ... "polyarteritis nodosa and allied conditions". When using the influential classification known as the "Chapel Hill Consensus ...
She has polyarteritis nodosa. "Kamkasomphou Thu - profile". IPTTC.org. ITTF Para Table Tennis. Retrieved 14 December 2019. " ...
He called it 'word blindness'.) First to describe polyarteritis nodosa. First to describe progressive bulbar paralysis. First ... Polyarteritis nodosa. Named with Rudolf Robert Maier (1824-1888). The following eponymous terms are considered archaic: ...
"The Ocular Manifestations of Polyarteritis Nodosa". Quarterly Journal of Medicine. New Series. Oxford: Oxford University Press ...
January 1996). "Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients". ... Churg and Strauss noted three features which distinguished their patients from other patients with periarteritis nodosa but ... Churg J, Strauss L (March-April 1951). "Allergic granulomatosis, allergic angiitis, and periarteritis nodosa". The American ... "periarteritis nodosa", accompanied by hypereosinophilia and severe asthma. ...
Other underlying disorders include vasculitides such as polyarteritis nodosa. Other causes of edema include heart failure, ...
The vasculitis seen in DADA2 is similar to polyarteritis nodosa (PAN), often leading to misdiagnosis. However, DADA2 patients ... April 2021). "Biologic drugs in the treatment of polyarteritis nodosa and deficit of adenosine deaminase 2: A narrative review ... October 2017). "ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre ... March 2014). "Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy". The New England Journal of Medicine. 370 ( ...
Polyarteritis nodosa of unknown mechanism can cause testicular pain. It is often associated with aneurysms and Hepatitis B. The ...
Liebowitz J, Hellmann DB1, Schnappauf O (2019) Thirty years of followup in 3 patients with familial polyarteritis nodosa due to ... An association with polyarteritis nodosa has been reported. The enzyme adenosine deaminase is encoded by the ADA gene on ...
The diagnosis is polyarteritis nodosa, a rare inflammation of the arteries. Ed probably has only months to live. He agrees to ... When Lou attempts to inform Ed that the cortisone may be negatively affecting him, Ed reminds her that his polyarteritis will ...
Polyarteritis nodosa is more common in people with hepatitis B infection. A number of different tests are available to ... Trepo C, Guillevin L (May 2001). "Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against ... polyarteritis nodosa) are HBV carriers. HBV-associated nephropathy has been described in adults but is more common in children ... polyarteritis nodosa), membranous glomerulonephritis, and papular acrodermatitis of childhood (Gianotti-Crosti syndrome). The ...
Toura died of polyarteritis nodosa in 1993 at the age of 62. The Sun's Burial (1960) as Masa Night and Fog in Japan (1960) as ...
Polyarteritis nodosa has been associated with underlying hairy cell leukemia in certain cases. Autoimmune diseases may also go ...
In addition, he co-authored the first reports on hepatitis B-associated polyarteritis nodosa; early reports on twins with lupus ...
Some examples of this group include granulomatosis with polyangiitis, polyarteritis nodosa, Behçet's disease, and HSP. Gonzalez ...
Polyarteritis Nodosa: PAN is another autoimmune disease in which the body's immune system attacks small and medium-sized ... Rheumatoid arthritis (RA), Wegner's granulomatosis (WG), and Polyarteritis Nodosa (PAN) are the most common systemic conditions ...
... polyarteritis nodosa, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis. This results in ... clinical and laboratory profiles of cutaneous polyarteritis nodosa patients: Report of 22 cases and literature review". ...
He developed therapies for formerly fatal diseases such as polyarteritis nodosa, granulomatosis with polyangiitis, and ... members of the American Rheumatism Association ranked Fauci's work on the treatment of polyarteritis nodosa and granulomatosis ...
In particular, old pathological descriptions from Western countries of infantile polyarteritis nodosa coincide with reports of ... Other diseases involving necrotizing vasculitis include polyarteritis nodosa, granulomatosis with polyangiitis, Henoch- ...
... s are sometimes involved in development of cerebral vasculitis and generalized polyarteritis nodosa like ...
Similarly, vasculitides such as Takayasu's arteritis, giant cell arteritis, polyarteritis nodosa, and Behçet's disease have ...
... and polyarteritis nodosa. Inflammation may also affect the lungs. Hematologic issues include macrocytic anemia, a low platelet ...
Other causes include rupture of renal artery or an arteriovenous malformation, polyarteritis nodosa, cystic medial necrosis, ...
A specific cause of the infarction should be looked for, such as diabetes, polyarteritis nodosa (inflammatory damage of vessels ...
Polyarteritis nodosa (Articles lacking sources from July 2023, All articles lacking sources, Articles with short description, ...
ANCA-associated vasculitides Polyarteritis nodosa List of cutaneous conditions Granulomatosis with polyangitis Nagai Y, ...
Inflammatory diseases of the blood vessels, like giant-cell arteritis, polyarteritis nodosa, Churg-Strauss syndrome, ...
The major types are given in the table below: Takayasu's arteritis, polyarteritis nodosa and giant cell arteritis mainly ... Polyarteritis nodosa Small vessel: Behçet's syndrome, Eosinophilic granulomatosis with polyangiitis, Cutaneous vasculitis, ...
... polyarteritis nodosa, Sjogren's syndrome, and Lyme disease. Research has come to the consensus that AIED is the result of ...
Polyarteritis nodosa rarely affects the blood vessels of the lungs and this feature can help to differentiate it from other ... In polyarteritis nodosa, small aneurysms are strung like the beads of a rosary, therefore making this "rosary sign" an ... Polyarteritis nodosa is more common in people with hepatitis B infection. The medical eponyms Kussmaul disease or Kussmaul- ... 2], Entry in Polyarteritis Nodosa Follow-up article "Bigger Than Life". The Criterion Collection. Retrieved 2021-07-16. ( ...
Classic polyarteritis nodosa (PAN or c-PAN) is a systemic vasculitis characterized by necrotizing inflammatory lesions that ... encoded search term (Polyarteritis Nodosa) and Polyarteritis Nodosa What to Read Next on Medscape ... Coexistence of polyarteritis nodosa and psoriatic arthritis in a child: an unreported association: Polyarteritis nodosa and ... 5, 6] The term periarteritis nodosa was changed to polyarteritis nodosa in the mid-1900s to reflect the transmural inflammation ...
Colchicine seems to confer good benefit-risk balance in cutaneous polyarteritis nodosa without peripheral sensory neuropathy. ... Background: Cutaneous polyarteritis nodosa is a form of medium-sized vessel vasculitis. Despite a disabling and prolonged ... Efficacy and safety of treatments in cutaneous polyarteritis nodosa: A French observational retrospective study J Am Acad ... Conclusion: Colchicine seems to confer good benefit-risk balance in cutaneous polyarteritis nodosa without peripheral sensory ...
Cookies help us deliver our services. By using our services, you agree to our use of cookies. ...
Two cases of polyarteritis nodosa and one case of pityriasis rosea-like drug eruption. Clin Exp Rheumatol 2000; 18(1): 81-5. 24 ... Polyarteritis nodosa (PAN) has been reported as a rare complication of natural infection with hepatitis B virus. Thus, ... Cutaneous polyarteritis nodosa in a child following hepatitis B vaccination. Eur J Dermatol 2009; 19(4): 400-1. ... Cutaneous polyarteritis nodosa following hepatitis B vaccination]. Ann Dermatol Venereol 2003; 130(2 Pt 1): 205-7. ...
Objective: To determine the long-term outcome of patients with polyarteritis nodosa (PAN), microscopic polyangiitis (MPA), and ... Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective ...
The occurrence of renal vein thrombosis in a case each of polyarteritis nodosa and the Henoch-Schoenlein syndrome is reported. ... Renal vein thrombosis in cases of polyarteritis nodosa and of the Henoch-Schoenlein syndrome ... Renal vein thrombosis in cases of polyarteritis nodosa and of the Henoch-Schoenlein syndrome ...
Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...
polyarteritis nodosa Last reviewed 01/2018. Polyarteritis nodosa (PAN) is a recurrent necrotising vasculitis of medium and ...
Hepatitis B has also been associated with polyarteritis nodosa. What are the symptoms of Polyarteritis Nodosa?. *Abdominal pain ... How is Polyarteritis Nodosa treated?. As of today, there is not a cure for PAN, but symptoms can be managed. The treatment is ... How is Polyarteritis Nodosa diagnosed?. The diagnosis of PAN is based on physical exam, signs and symptoms, and some laboratory ... What is Polyarteritis Nodosa?. This condition is characterized by vasculitis, which is an inflammation of small and medium ...
Polyarteritis nodosa. Diseases that fall under the classification of polyarteritis/periarteritis nodosa (PAN) probably ... How is polyarteritis nodosa associated with end-stage renal disease (ESRD)?. How are cholesterol emboli associated with end- ... Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med. 1992 Apr 1. 116 (7):605-6. [QxMD MEDLINE Link]. ... Polyarteritis nodosa, granulomatosis with polyangiitis, Henoch-Schönlein purpura, scleroderma, and otherwise nonspecified ...
Classic polyarteritis nodosa (PAN or c-PAN) is a systemic vasculitis characterized by necrotizing inflammatory lesions that ... encoded search term (Polyarteritis Nodosa) and Polyarteritis Nodosa What to Read Next on Medscape ... Coexistence of polyarteritis nodosa and psoriatic arthritis in a child: an unreported association: Polyarteritis nodosa and ... Polyarteritis Nodosa Differential Diagnoses. Updated: Jan 12, 2016 * Author: Dana Jacobs-Kosmin, MD, FACP; Chief Editor: ...
... imaging findings and much more of Polyarteritis Nodosa (PAN) a common form of Vasculitis ... Polyarteritis Nodosa (PAN). Home » Endovascular Education » Vascular Interventional Radiology » Arterial Pathology » Vasculitis ... The cause of polyarteritis nodosa is not fully understood, but it is thought to be an autoimmune disorder in which the bodys ... Diagnosis of polyarteritis nodosa is typically made based on a combination of clinical symptoms, imaging tests such as CT scans ...
Background Childhood Polyarteritis nodosa (PAN) is a systemic vasculitis with necrotizing inflammation of medium- and small- ... A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report, 2021 (990.6Kb) ... A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report. Pediatr Rheumatol. 2021 Dec ... A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report. ...
Polyarteritis Nodosa (PN). Polyarteritis nodosa (PN) is also known as Kussmaul disease, Kussmaul-Maier disease, or infantile ... polyarteritis nodosa. Its an inflammation of the medium and smaller arteries that carry blood from your heart to your organs ...
Periarteritis nodosa (155441006); Polyarteritis nodosa (155441006); PAN - Polyarteritis nodosa (155441006). Modes of ... Polyarteritis nodosa.. Forbess L, Bannykh S. Rheum Dis Clin North Am 2015;41(1):33-46, vii. doi: 10.1016/j.rdc.2014.09.005. ... Polyarteritis nodosa.. Bilginer Y, Ozen S. Curr Opin Pediatr 2022 Apr 1;34(2):229-233. doi: 10.1097/MOP.0000000000001106. PMID ... Polyarteritis nodosa.. Bilginer Y, Ozen S. Curr Opin Pediatr 2022 Apr 1;34(2):229-233. doi: 10.1097/MOP.0000000000001106. PMID ...
considered in patients suspected of having polyarteritis nodosa in the setting of being unable to obtain a histologic diagnosis ...
Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series.. Tanaz A Kermani, Erin K ... OBJECTIVE: To describe the clinical features, treatment, and outcomes of polyarteritis nodosa (PAN)-like vasculitis in ...
Polyarteritis Nodosa (PAN) - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the MSD Manuals - Medical ... The nodules in PAN resemble erythema nodosum Erythema Nodosum Erythema nodosum is a specific form of panniculitis characterized ... Hepatitis B-related polyarteritis nodosa Treatment is aimed at rapidly suppressing inflammation and antiviral therapy. A short ... The cause of polyarteritis nodosa is unknown, but immune mechanisms appear to be involved. The variety of clinical and ...
Cutaneous Polyarteritis Nodosa (cPAN) was first described in 1931. cPAN is considered a rare disease, its true incidence is ... Cutaneous Polyarteritis Nodosa (cPAN) was first described in 1931. cPAN is considered a rare disease, its true incidence is ... Haviv, R., Capua, M., Amir, J. et al. Cutaneous polyarteritis nodosa successfully treated with topical diflucortolone valerate ... Cutaneous polyarteritis nodosa successfully treated with topical diflucortolone valerate - a case report & review of the ...
Polyarteritis nodosa. If you are taking one or more of these medications for your arthritis, you may be at high risk for ...
Polyarteritis Nodosa. Polyarteritis Nodosa (PAN) is a form of vasculitis (inflammation in the wall of blood vessels). PAN ... Learn more about Polyarteritis Nodosa.. Polymyalgia Rheumatica. Polymyalgia Rheumatica (PMR) is an inflammatory condition which ...
ADA2 deficiency is sometimes described as a form of polyarteritis nodosa (PAN), a disorder that causes inflammation of blood ... as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017 Oct; ... Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014 Mar 6;370(10):921-31. doi: 10.1056/ ...
Polyarteritis nodosa. NA. NA. Cyclophosphamide, corticosteroids. 2. Visceral. (11). 6. Spain. 55/M. Psoriatic arthritis. ... Visceral leishmaniasis in a patient treated for polyarteritis nodosa. Clin Exp Rheumatol. 2003;21(S32):S121-3.PubMedGoogle ...
... polyarteritis nodosa; polymyalgia rheumatica, temporal arteritis; Raynaud disease/Raynaud syndrome; reactive arthritis, ...
Polyarteritis Nodosa. * Posterior Cerebral Artery Stroke. * Primary CNS Lymphoma. * Primary Lateral Sclerosis ...
Systemic vasculitides affecting the hand are mostly represented by polyarteritis nodosa (PAN). PAN is a systemic necrotising ...
Classic Polyarteritis Nodosa. *Cutaneous Lupus Erythematosus. *Dermatomyositis. *Difficulty With Walking. *Dry Eyes ...
ICD-10 Central Data Repository.. ICD10 Codes M300 (Polyarteritis nodosa) - M342 (Systemic sclerosis induced by drug and ... Polyarteritis nodosa HTML , TXT , Mapping ICD-10 Code: M301 (M30.1) Code Type: Diagnosis Description: Polyarteritis with lung ... Other conditions related to polyarteritis nodosa HTML , TXT , Mapping ICD-10 Code: M31 (M31) Code Type: Diagnosis Description: ... Showing codes M300 (Polyarteritis nodosa) - M342 (Systemic sclerosis induced by drug and chemical). ICD-10 Code: M300 (M30.0) ...
Stanson AW, Friese JL, Johnson CM, McKusick MA, Breen JF, Sabater EA, et al. Polyarteritis nodosa: Spectrum of angiographic ... Mo H, Cho S, Jae HJ, Min SK. Hybrid surgery to treat multiple visceral aneurysms secondary to polyarteritis nodosa. Vasc ... Levin S, Graber J, Ehrenwald E, Skeik N. Polyarteritis nodosa-induced pancreaticoduodenal artery aneurysmal rupture. Int J ... Polyarteritis nodosa (PAN) is necrotizing vasculitis involving medium- or small-sized arteries and leads to microaneurysms ...
  • Polyarteritis nodosa (PAN) is a systemic necrotizing inflammation of blood vessels (vasculitis) affecting medium-sized muscular arteries, typically involving the arteries of the kidneys and other internal organs but generally sparing the lungs' circulation. (wikipedia.org)
  • In polyarteritis nodosa, small aneurysms are strung like the beads of a rosary, therefore making this "rosary sign" an important diagnostic feature of the vasculitis. (wikipedia.org)
  • Classic polyarteritis nodosa (PAN or c-PAN) is a systemic vasculitis characterized by necrotizing inflammatory lesions that affect medium-sized and small muscular arteries, preferentially at vessel bifurcations. (medscape.com)
  • formerly called microscopic polyarteritis) is an ANCA-associated systemic vasculitis that has some features similar to those of classic PAN, with the additional involvement of renal glomeruli and pulmonary capillaries. (medscape.com)
  • Cutaneous polyarteritis nodosa is a form of medium-sized vessel vasculitis. (nih.gov)
  • Do Vaccines Cause Vasculitis or Polyarteritis Nodosa? (vaccinesafety.edu)
  • To determine the long-term outcome of patients with polyarteritis nodosa (PAN), microscopic polyangiitis (MPA), and Churg-Strauss syndrome (CSS), to compare the long-term outcome with the overall French population, to evaluate the impact on outcome of the type of vasculitis, prognostic factors, and treatments administered at diagnosis, and to analyze treatment side effects and sequelae. (nih.gov)
  • Polyarteritis nodosa (PAN) is a recurrent necrotising vasculitis of medium and small muscular arteries. (gpnotebook.com)
  • Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries, with occasional involvement of small muscular arteries. (lavascular.com)
  • Background Childhood Polyarteritis nodosa (PAN) is a systemic vasculitis with necrotizing inflammation of medium- and small-sized arteries. (gencat.cat)
  • 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. (nih.gov)
  • Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series. (qxmd.com)
  • To describe the clinical features, treatment, and outcomes of polyarteritis nodosa (PAN)-like vasculitis in association with minocycline therapy. (qxmd.com)
  • Polyarteritis nodosa is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries and occasionally affects small muscular arteries, resulting in secondary tissue ischemia. (msdmanuals.com)
  • ADA2 deficiency is sometimes described as a form of polyarteritis nodosa (PAN), a disorder that causes inflammation of blood vessels throughout the body (systemic vasculitis). (medlineplus.gov)
  • Cutaneous polyarteritis nodosa (CPN) is an uncommon form of vasculitis of the small-and medium-sized arteries in the reticular dermis and subcutaneous tissue. (annals.edu.sg)
  • Medium vessel vasculitis typically affects arteries supplying the kidneys, bowels, brain or heart (e.g. polyarteritis nodosa, Kawasaki disease). (printo.it)
  • Types of medium-vessel vasculitis are Kawasaki disease and polyarteritis nodosa. (mountsinai.org)
  • The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. (medscape.com)
  • Diagnosis and classification of polyarteritis nodosa. (medscape.com)
  • For information on pediatric PAN, see Childhood Polyarteritis Nodosa . (medscape.com)
  • EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. (nih.gov)
  • Polyarteritis nodosa rarely affects the blood vessels of the lungs and this feature can help to differentiate it from other vasculitides that may have similar signs and symptoms (e.g., granulomatosis with polyangiitis or microscopic polyangiitis). (wikipedia.org)
  • Polyarteritis nodosa, granulomatosis with polyangiitis, Henoch-Schönlein purpura, scleroderma, and otherwise nonspecified vasculitides also were reported to have caused ESRD during this period. (medscape.com)
  • Vasculitides (polyarteritis nodosa, granulomatosis with polyangiitis, temporal arteritis). (clevelandclinic.org)
  • Periarteritis nodosa was a term used from the mid-1800s to the 1900s to describe a spectrum of systemic vasculitic disorders, including diseases that manifested as arterial aneurysms, as well as those that caused diffuse necrotizing glomerulonephritis. (medscape.com)
  • [ 5 , 6 ] The term periarteritis nodosa was changed to polyarteritis nodosa in the mid-1900s to reflect the transmural inflammation of arteries caused by this disorder. (medscape.com)
  • Kussmaul A, Maier R. Ueber eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. (medscape.com)
  • Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. (medscape.com)
  • We aimed to describe treatment efficacy and safety in patients with cutaneous polyarteritis nodosa. (nih.gov)
  • Colchicine seems to confer good benefit-risk balance in cutaneous polyarteritis nodosa without peripheral sensory neuropathy. (nih.gov)
  • Cutaneous Polyarteritis Nodosa (cPAN) was first described in 1931. (biomedcentral.com)
  • Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. (medscape.com)
  • The diagnosis of polyarteritis nodosa (PAN) can be difficult because of the spectrum of clinical manifestations and the rarity of the disease. (medscape.com)
  • Diagnosis of polyarteritis nodosa is typically made based on a combination of clinical symptoms, imaging tests such as CT scans or MRIs, and biopsy of affected tissue. (lavascular.com)
  • While there is no cure for polyarteritis nodosa, early diagnosis and treatment can help prevent serious complications and improve outcomes for individuals with the disease. (lavascular.com)
  • Polyarteritis nodosa (PAN) has been reported as a rare complication of natural infection with hepatitis B virus. (vaccinesafety.edu)
  • Hepatitis B has also been associated with polyarteritis nodosa. (rockvillecentredoctor.com)
  • Polyarteritis nodosa related to hepatitis B virus. (medscape.com)
  • Mononeuritis multiplex develops in more than 70% of patients with polyarteritis nodosa because of damage to arteries supplying large peripheral nerves. (wikipedia.org)
  • Juvenile polyarteritis: results of a multicenter survey of 110 children. (medscape.com)
  • Polyarteritis nodosa, or PAN, is a rare autoimmune disorder that causes inflammation of the small and medium-sized arteries. (lavascular.com)
  • The cause of polyarteritis nodosa is not fully understood, but it is thought to be an autoimmune disorder in which the body's immune system mistakenly attacks healthy tissue. (lavascular.com)
  • What are the symptoms of Polyarteritis Nodosa? (rockvillecentredoctor.com)
  • Symptoms of polyarteritis nodosa can vary depending on the specific organs affected, but can include abdominal pain, fever, weight loss, and weakness. (lavascular.com)
  • Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. (medscape.com)
  • The occurrence of renal vein thrombosis in a case each of polyarteritis nodosa and the Henoch-Schoenlein syndrome is reported. (bmj.com)
  • The patient met the ACR diagnostic criteria for polyarteritis nodosa. (sanevax.org)
  • It is important for individuals who are at risk for polyarteritis nodosa to be monitored by a healthcare provider and receive regular check-ups to ensure the condition is properly managed. (lavascular.com)
  • Polyarteritis nodosa (PN) is also known as Kussmaul disease, Kussmaul-Maier disease, or infantile polyarteritis nodosa. (healthline.com)
  • Polyarteritis nodosa (PAN) is rare (about 2 to 33 cases/million). (msdmanuals.com)
  • A history of early investigation in polyarteritis nodosa. (medscape.com)
  • Iloprost in the management of leg ulcer in polyarteritis nodosa. (minervamedica.it)
  • The aim is to review recent reports on childhood polyarteritis nodosa, including recent reports on treatment and outcome. (nih.gov)
  • We also aim to highlight differences of childhood polyarteritis nodosa with deficiency of ADA2 as well as adult-onset disease. (nih.gov)
  • We need collaborative work to define management and treatment strategies for childhood polyarteritis nodosa. (nih.gov)
  • For information on pediatric PAN, see Childhood Polyarteritis Nodosa . (medscape.com)
  • EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. (nih.gov)
  • 3. Childhood polyarteritis nodosa in autoimmune lymphoproliferative syndrome. (nih.gov)
  • Ocular presentation of polyarteritis nodosa. (nih.gov)
  • Polyarteritis nodosa rarely affects the blood vessels of the lungs and this feature can help to differentiate it from other vasculitides that may have similar signs and symptoms (e.g., granulomatosis with polyangiitis or microscopic polyangiitis). (wikipedia.org)
  • Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. (medscape.com)
  • Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. (medlineplus.gov)
  • We report a case of visceral leishmaniasis in a patient receiving steroids and cyclophosphamide for polyarteritis nodosa. (nih.gov)
  • Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide]. (nih.gov)
  • Polyarteritis nodosa, presenting as life-threatening gastrointestinal hemorrhage in a liver transplant recipient. (nih.gov)
  • Polyarteritis nodosa presenting as massive upper gastrointestinal hemorrhage. (arizona.edu)
  • Dive into the research topics of 'Polyarteritis nodosa presenting as massive upper gastrointestinal hemorrhage. (arizona.edu)
  • Blood vessel necrosis in laboratory animals is most often seen as one component of the spectrum of lesions of polyarteritis nodosa and rarely presents as an individual lesion without other associated changes. (nih.gov)
  • Polyarteritis nodosa may present segmentally, and multiple stages of inflammation (acute, chronic, and healed lesions) may be encountered within the same animal. (nih.gov)
  • The effect of some factors which modify experimental tuberculin hypersensitivity in guinea pigs was studied in 10 patients with rheumatoid arthritis and one patient with polyarteritis nodosa. (erowid.org)
  • Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. (medscape.com)
  • Attempts at healing, typified by fibrosis, may also be present in chronic polyarteritis. (nih.gov)
  • Before the term Kawasaki disease (KD), it was reported as syndrome of mucocutaneous lymph node with infantile polyarteritis nodosa which was common among younger Asian population. (scirp.org)
  • The occurrence of renal vein thrombosis in a case each of polyarteritis nodosa and the Henoch-Schoenlein syndrome is reported. (bmj.com)
  • Mononeuritis multiplex develops in more than 70% of patients with polyarteritis nodosa because of damage to arteries supplying large peripheral nerves. (wikipedia.org)
  • Patients with systemic polyarteritis nodosa have involvement of other organs, including the gastrointestinal tract, heart and/or kidneys. (vasculitisfoundation.org)
  • Nonspecific, firm, tender subcutaneous nodules without livedo reticularis and/or systemic involvement may be the first sign of polyarteritis nodosa (PAN). (medscape.com)
  • Polyarteritis nodosa is also observed in the aged hamster, with renal, testicular, and coronary arteries affected. (nih.gov)
  • Polyarteritis nodosa is a serious inflammatory blood vessel disease. (medlineplus.gov)
  • Though it is generally considered a spontaneous disease, polyarteritis nodosa may be exacerbated by administration of xenobiotics. (nih.gov)
  • Additionally, the lesions of polyarteritis nodosa may be induced by administration of some xenobiotics, which may prove difficult to distinguish from the spontaneous disease. (nih.gov)
  • Polyarteritis nodosa (PAN) is a systemic disease which involves the kidneys in 70% of cases. (istanbul.edu.tr)
  • Fibrinoid necrosis as part of spontaneous polyarteritis nodosa often involves the pancreatic and mesenteric vessels of rats. (nih.gov)
  • There are a number of disorders that have features similar to polyarteritis nodosa. (medlineplus.gov)
  • Luqmani R, Awisat A. Polyarteritis nodosa and related disorders. (medlineplus.gov)
  • Lesions similar to polyarteritis nodosa have been seen in repeatedly bred rats and in rats with induced hypertension. (nih.gov)
  • Polyarteritis nodosa (PAN) is rare (about 2 to 33 cases/million). (msdmanuals.com)
  • No specific lab tests exist for diagnosing polyarteritis nodosa. (wikipedia.org)
  • No specific lab tests are available to diagnose polyarteritis nodosa. (medlineplus.gov)
  • Follow this link to review classifications for Polyarteritis nodosa in Orphanet. (nih.gov)
  • A history of early investigation in polyarteritis nodosa. (medscape.com)